David Altshuler, EVP, Global Research and CSO at VERTEX PHARMACEUTICALS INC / MA (VRTX), sold 14,566 shares at $420.79 ($6.1M) on 2024-02-20, disclosed to the SEC on 2024-02-21.
Scheduled sale ($6.1M) by EVP, Global Research and CSO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $424.01 | 3,750 | $1.6M | 25.9% |
| 2 | $420.58 | 2,812 | $1.2M | 19.3% |
| 3 | $420.79 | 4,002 | $1.7M | 27.4% |
| 4 | $420.79 | 4,002 | $1.7M | 27.4% |
| Total | $421.58 avg | 14,566 | $6.1M | 100% |
| Filing → |
| VRTX | SELL | 2025-03-12 | $1.6M | — | Filing → |
| VRTX | SELL | 2025-03-05 | $1.6M | — | Filing → |
| VRTX | SELL | 2025-02-28 | $611K | — | Filing → |